HMGB1 EXPRESSION AND PROTECTIVE ROLE OF SEMAPIMOD IN NEC

• US 20070282005A1
• Filed: 06/01/2006
• Published: 12/06/2007
• Est. Priority Date: 06/01/2005
• Status: Active Grant

• Current Assignee: Ferring BV (Ferring Holding SA), University of Pittsburgh of The Commonwealth System of Higher Education
• Original Assignee: Cytokine PharmaSciences Inc. (Ferring Holding SA), University of Pittsburgh of The Commonwealth System of Higher Education
• Inventors: De La Cruz, Vidal, Ford, Henri, Zamora, Ruben, Sielecki-Dzurdz, Thais
• Granted Patent: US 7,795,314 B2
• Time in Patent Office: Days
• US Class Current: 514/616
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 33/06 Antimalarials

Abstract

Methods are described, which include the administration of semapimod or guanylhydrazone containing compounds, salt thereof, or a combination of the compound and a salt thereof for the inhibition, treatment, and/or prevention of any of NEC, a condition associated with the release of HMGB1, a condition associated with the release of iNOS protein, a condition associated with the release of Bax protein, a condition associated with the release of Bad protein, a condition associated with the release of COX-2 protein, or a condition associated with the release of RAGE, or a combination thereof to a subject in need thereof.

Claims

1. A method, comprising administering a compound having the following formula:

2. The method of claim 1, wherein the subject is a human subject.

3. The method of claim 1, wherein the subject is a human infant.

4. The method of claim 1, wherein the subject is a human subject that exhibits one or more condition selected from the group consisting of NEC, low-birth weight, formula feeding, bacterial colonization of the gut, hypoxia, a condition associated with the release of HMGB1, a condition associated with the release of RAGE, a condition associated with the release of Bax protein, a condition associated with the release of Bad protein, a condition associated with the release of COX-2 protein, or a condition associated with the release of iNOS protein, or a combination thereof.

5. The method of claim 1, wherein the compound is in the salt form.

6. The method of claim 1, wherein the compound is salt of a carboxylic acid having the following formula I or II:

7. The method of claim 1, wherein the compound, salt thereof, or a combination of the compound and a salt thereof, is administered in the form of a composition further comprising at least one carrier.

8. A method, comprising administering a compound having the formula:

9. The method of claim 8, wherein the subject is a human subject.

10. The method of claim 8, wherein the subject is a human infant.

11. The method of claim 8, wherein the subject is a human subject that exhibits one or more condition selected from the group consisting of NEC, low-birth weight, formula feeding, bacterial colonization of the gut, hypoxia, a condition associated with the release of HMGB1, a condition associated with the release of RAGE, a condition associated with the release of Bax protein, a condition associated with the release of Bad protein, a condition associated with the release of COX-2 protein, or a condition associated with the release of iNOS protein, or a combination thereof.

12. The method of claim 8, wherein the compound, salt thereof, or combination of the compound and a salt thereof, is administered together with at least one carrier.

13. The method of claim 8, wherein the compound is in the salt form.

14. The method of claim 8, wherein the compound is salt of a carboxylic acid having the following formula I or II: